Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

This 2021 study investigates the antitumor effects of low-dose naltrexone (LDN) on cervical cancer. LDN treatment upregulated the expression of the opioid growth factor receptor (OGFr) and suppressed the PI3K/AKT/mTOR signaling pathway, leading to reduced proliferation, migration, and invasion of cervical cancer cells in vitro. In vivo, LDN inhibited tumor